Eli Lilly and Company says one-year Phase 3b data from TOGETHER-PsO and TOGETHER-PsA show sustained or deeper improvements when Zepbound and Taltz are used together in patients living with psoriatic disease and obesity.
The FDA has approved Eli Lilly and Company’s Mounjaro to reduce cardiovascular death, heart attack and stroke risk in high-risk adults with type 2 diabetes, significantly broadening the clinical case for tirzepatide beyond glucose control and weight reduction.
Ascletis says ASC37 beat tirzepatide in obese mice, but human dosing, safety and durability remain untested ahead of a planned U.S. IND.
Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.
Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.
Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
GLP-1 drugs drive weight loss, but rebound and body composition gaps remain. Caliway’s CBL-514 may test the next obesity frontier.
Caliway’s CBL-514 heads to ADA 2026 with tirzepatide combination data. Read what this could change in obesity treatment strategy.
Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.